Response to Antivirals for HCV in HIV/HCV Co-infection
Response to Antivirals for HCV in HIV/HCV Co-infection
Unadjusted analyses suggested that PEG-IFN alpha 2a was associated with higher SVR than PEG-IFN alpha 2b; this result seemed more prominent in patients with genotype 2 and genotype 3 infection than in patients with genotype 1 infection (Table 2). However, a much greater proportion of patients treated with PEG-IFN alpha 2b received a lower than recommended dose of PEG-IFN than patients treated with PEG-IFN alpha 2a. After adjusting for dose of PEG-IFN (at or below recommended) as well as genotype, baseline hepatitis C viral load, race, diabetes, baseline anaemia, AST/ALT ratio, starting ribavirin dose and erythropoietin use, receipt of PEG-IFN alpha 2a vs. 2b was no longer associated with SVR (AOR 0.72, 95% CI 0.2–2.8) among patients of all genotypes. Small sample size precluded such multivariate-adjusted analyses limited to genotype 2 and 3 patients alone.
Association Between Type of Pegylated Interferon Alpha (2a Vs. 2b) and SVR
Unadjusted analyses suggested that PEG-IFN alpha 2a was associated with higher SVR than PEG-IFN alpha 2b; this result seemed more prominent in patients with genotype 2 and genotype 3 infection than in patients with genotype 1 infection (Table 2). However, a much greater proportion of patients treated with PEG-IFN alpha 2b received a lower than recommended dose of PEG-IFN than patients treated with PEG-IFN alpha 2a. After adjusting for dose of PEG-IFN (at or below recommended) as well as genotype, baseline hepatitis C viral load, race, diabetes, baseline anaemia, AST/ALT ratio, starting ribavirin dose and erythropoietin use, receipt of PEG-IFN alpha 2a vs. 2b was no longer associated with SVR (AOR 0.72, 95% CI 0.2–2.8) among patients of all genotypes. Small sample size precluded such multivariate-adjusted analyses limited to genotype 2 and 3 patients alone.